New Triple-Threat attack on tough pancreatic cancers
NCT ID NCT05688215
First seen Jan 16, 2026 · Last updated Apr 11, 2026 · Updated 13 times
Summary
This study is testing a new combination of three drugs for people with pancreatic cancer that is difficult or impossible to remove with surgery. The goal is to see if adding two immunotherapy drugs to standard chemotherapy is safe and can shrink tumors better than chemo alone. Researchers will measure if the treatment helps patients live longer without their cancer getting worse and, for some, if it makes surgery possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonemoto,Lisa
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.